Discure Technologies, a Petach-Tikva, Israel-based developer of the Discure System, a bioelectronic implantable device for the treatment of degenerative disc disease (DDD), raised $16M in funding.
The round consisted of $11M in a Series A financing round, following a SAFE (Simple Agreement for Future Equity) raise of $5M. The Series A round was led by Bold Capital Partners, Supernova Invest and Sanara Capital, with participation from other investors.
The company intends to use the funds to expand operations and its development efforts.
Founded by Rainbow Medical, and led by CEO Yuval Mandelbaum, Discure Technologies is developing a minimally invasive, implantable bioelectronic device designed to treat and reverse degenerative disc disease (DDD) by actively controlling the reintroduction of fluid, oxygen, and nutrients into the degenerated disc.
FinSMEs
10/09/2024